| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
ChiCTR1800014499: The observation of clinical changes in refractory patients with type 2 diabetes before and after using dapagliflozin |
|
|
| Not yet recruiting | N/A | 40 | | using dapagliflozin | Tianjin Fourth Central Hospital; Tianjin Fourth Central Hospital, by myself | type 2 diabetes | | | | |
ChiCTR1800015830: The effect of dapagliflozin on blood uric acid in diabetic patients |
|
|
| Recruiting | N/A | 60 | | offer dapagliflozin ;none | Tianjin Fourth Central Hospital; Level of the institution：, Self-financing | type 2 diabetes | | | | |
ChiCTR1800019332: Effects of Dapagliflozin on blood glucose and metabolic parameters in patients with type 2 diabetes mellitus |
|
|
| Not yet recruiting | N/A | 50 | | Dapagliflozin | Qingdao Central Hospital; Qingdao Central Hospital, Self-finance | Diabetes | | | | |
ChiCTR1800017885: Multicenter prospective cohort study of efficacy, weight control, and safety in newly-diagnosed type 2 diabetes: Triple Combination Therapy using Metformin, Saxagliptin plus Dapagliflozin Versus Premixed Insulin |
|
|
| Not yet recruiting | N/A | 130 | | Subcutaneous injection therapy with insulin aspart 30.:The initial total dose is 0.3U-0.5U/Kg, 2 /day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level ;Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin. Adjusting dose according to the blood glucose level | Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing | Type 2 Diabetes Mellitus | | | | |
ChiCTR1800015072: Clinical effect of Andatang on uric acid metabolism and renal tubular function in type 2 diabetes mellitus. |
|
|
| Not yet recruiting | N/A | 550 | | Dapagliflozin Tablets(Andatang) | Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University; Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, None | type 2 diabetes mellitus | | | | |
ChiCTR1800019864: Efficacy of dapagliflozin versus liraglutide in overweight and obese patients with inadequately controlled type 2 diabetes with insulin therapy |
|
|
| Not yet recruiting | N/A | 80 | | Dapagliflozin ;Liraglutide | Tianjin Medical University Metabolic Diseases Hospital; Level of the institution：, Self-raised funds | diabetes | | | | |
ChiCTR1800017353: The Effect of dapagliflozin on hemodynamics in patients with acute heart failure complicated with type 2 diabetes |
|
|
| Recruiting | N/A | 50 | | dapagliflozin 10 mg + insulin ;insulin | Shanghai Chest Hospital; Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine | Hearrt Failure | | | | |
| Recruiting | N/A | 30 | Europe | SGLT2 inhibitor, Dapagliflozin, Empagliflozin, Canagliflozin | University of Turin, Italy | Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes | 07/20 | 10/20 | | |
ChiCTR1800016123: Effect of metformin combined with dapagliflozin or saxagliptin on short-term insulin intensive in patients with Newly Diagnosed Type 2 Diabetes. |
|
|
| Recruiting | N/A | 120 | | Metformin ;Metformin+Acarbose Tablets ;Metformin+Saxagliptin ;Metformin+Dapagliflozin | Affiliated Hospital of Weifang Medical University; Affiliated Hospital of Weifang Medical University, National Natural Science Foundation of China | diabetes mellitus | | | | |
NCT04882813: Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data |
|
|
| Completed | N/A | 87727 | US | Dapagliflozin, Sitagliptin | Brigham and Women's Hospital | Chronic Kidney Disease | 06/21 | 06/21 | | |
ChiCTR1900026681: Analysis for different expressed of circrnas and urine proteomics in urine exosomes of patients with mild to moderate type 2 diabetic nephropathy to be treated by Dapagliflozin |
|
|
| Not yet recruiting | N/A | 10 | | Dapagliflozin | The Second Hospital of Jilin University; The Second Hospital of Jilin University, Health Commission of Jilin Province | Diabetes Mellitus | | | | |
NCT05045274: The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction |
|
|
| Not yet recruiting | N/A | 300 | NA | Dapagliflozin 10Mg Tab, aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally, DAPT, SC-anticoagulation, beta blockers, statin, Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload., Placebo | Assiut University | STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction | 06/22 | 09/22 | | |
EpiCAD, NCT06128096: The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD |
|
|
| Recruiting | N/A | 360 | RoW | Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Forxiga (Dapagliflozin), Jardiance (Empagliflozin) | Clinical Research Centre, Malaysia, University of Malaya, Ministry of Health, Malaysia | Coronary Artery Disease | 06/24 | 12/24 | | |
DAPA-AMI, NCT04717986: Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction |
|
|
| Completed | N/A | 188 | RoW | Dapagliflozin 10Mg Tab, Placebo | Instituto Mexicano del Seguro Social, Germán Ramón Bautista López, Luis Jonathan González, Rodolfo Guardado Mendoza, Gabriel Fernández Yáñez | Acute Myocardial Infarction, Cardiovascular Morbidity, Heart Failure, Angina, Unstable | 06/22 | 06/23 | | |
NCT06241638: Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers |
|
|
| Completed | N/A | 80 | RoW | Vitamin B12 0.5 MG/ACTUAT, Dapagliflozin 10mg Tab | Al-Balqa Applied University | Diabetes Mellitus | 06/23 | 06/23 | | |
SDHF, NCT05141552: The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure |
|
|
| Recruiting | N/A | 20 | RoW | Dapagliflozin 10Mg Tab, Control | RenJi Hospital | Hemodialysis Complication | 07/22 | 07/22 | | |
SAHARA, NCT04882358: Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion |
|
|
| Active, not recruiting | N/A | 24 | RoW | ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor, dapagliflozin | Sequana Medical N.V. | Heart Failure, Volume Overload | 08/22 | 12/24 | | |
| Not yet recruiting | N/A | 110 | | Dapagliflozin ;Placebo | Guizhou Provincial People's Hospital; Guizhou Provincial People's Hospital, self-finance | ST-segment elevation myocardial infarction | | | | |
NCT05418465: Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy |
|
|
| Recruiting | N/A | 100 | RoW | Huangqi Guizhi Wuwu decoction, Dapagliflozin | The First Affiliated Hospital of Dalian Medical University | Diabetic Nephropathies | 12/22 | 12/22 | | |
ChiCTR2100041868: The effect of dapagliflozin on anti-atherosclerosisin and atherosclerotic cardiovascular disease in patients with type 2 diabetes and metabolic syndrome: a randomized controlled study |
|
|
| Recruiting | N/A | 256 | | Dapagliflozin 10 mg is to be administered orally once daily. The addition of an alternative anti-diabetic agent (excluding another SGLT2 inhibitor) is be permitted 4 weeks after randomization. ;In the control group, either the dosage of current therapy is to be increased or a concomitant oral glucose-lowering drug (excluding the other SGLT2 inhibitors) is be added 4 weeks after randomization. | The First People's Hospital of Xuzhou; The First People's Hospital of Xuzhou, Project funding | Type 2 diabetes and metabolic syndrome | | | | |
NCT05727423: Dapagliflozin in the Treatment of Heart Failure |
|
|
| Active, not recruiting | N/A | 45 | RoW | | Helwan University | Heart Failure | 01/24 | 02/24 | | |
NCT06127212: Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets |
|
|
| Completed | N/A | 24 | RoW | Dapagliflozin 10 mg film-coated tablet, Test, Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia, Reference | Dexa Medica Group, PT Equilab International | Healthy | 03/23 | 05/23 | | |
ChiCTR2300069711: Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure: a cohort study |
|
|
| Recruiting | N/A | 424 | | N/A ;N/A | Beijing Anzhen Hospital, Capital Medical University ; Beijing Anzhen Hospital, Capital Medical University, self-financing | atrial fibrillation | | | | |
| Recruiting | N/A | 12 | Europe | Recompensation (guideline directed medical therapy) | Universität des Saarlandes | Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
ChiCTR2100047804: The effects of dapagliflozin on the contrast-induced nephropathy in coronary heart disease with type 2 diabetes result in renal insufficiency after percutaneous coronary intervention |
|
|
| Recruiting | N/A | 210 | | In the low-dose dapagliflozin group (5mg) and the high-dose dapagliflozin group (10mg), the first and second doses of dapagliflozin were given two days before coronary artery surgery, and the same dose was given again 24 hours later Dapagliflozin | Department of Cardiology, Zhongda Hospital of Southeast University Medical School; Zhongda Hospital of Southeast University Medical School, Self-funded | contrast-induced nephropathy | | | | |
| Recruiting | N/A | 160 | Europe | Dapagliflozin 10 milligrams [Farxiga], Placebo | University of Edinburgh, AstraZeneca, NHS Lothian | Heart Failure, Diabetic Cardiomyopathies | 07/28 | 07/28 | | |
NCT05335629: Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients |
|
|
| Completed | N/A | 54 | RoW | Dapagliflozin 10Mg Tab | Ain Shams University | Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular | 10/23 | 10/23 | | |
NCT06344247: Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease |
|
|
| Recruiting | N/A | 48 | RoW | RAS inhibitors：Losartan®️/Valsartan®️, dapagliflozin：Forxiga®️, simagliptin：Forxiga®️, Semaglutide®️ | RenJi Hospital | Obesity, Chronic Kidney Diseases | 09/25 | 12/25 | | |
| Completed | N/A | 2682052 | Europe, Japan, US | | AstraZeneca | Chronic Kidney Disease | 09/23 | 09/23 | | |
| Active, not recruiting | N/A | 150 | RoW | Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine | Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull | Diabetes Mellitus Type 2 | 10/23 | 10/24 | | |
NCT06065280: Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients |
|
|
| Recruiting | N/A | 80 | RoW | Empagliflozin 10 MG, Jardiance 10 mg, Dapagliflozin 10 MG, Forxiga 10 mg | Damanhour University | Heart Failure, Reduced Ejection Fraction Heart Failure | 03/24 | 03/24 | | |
NCT06226896: Effects of Dapagliflozin on Progression of Alport Syndrome |
|
|
| Recruiting | N/A | 200 | RoW | Dapagliflozin 10mg Tab, Dapagliflozin | Nanjing University School of Medicine | Alport Syndrome | 06/26 | 09/26 | | |
ChiCTR2000033664: A head-to-head study of SGLT2 inhibitors and ARB in patients with diabetes and proteinuria |
|
|
| Recruiting | N/A | 180 | | Taking dapagliflozin or ARB ;Basal treatment for the blood sugar control + oral Daglitel tablets 10mg for 24 weeks ;Basal treatment for the blood sugar control + oral Irbesartan tablets 10mg for 24 weeks | Huaian First People's Hospital; Huaian First People's Hospital, The International Science and Technology Cooperation Research Project (HAC1707) of Jiangsu Huai'an Science and Technology Bureau and the Project of Jiangsu Provincial Health Department (BK20191213) | Diabetic nephropathy | | | | |
NCT05347459: Cognitive Protective Effect of Newer Antidiabetic Drugs |
|
|
| Recruiting | N/A | 100 | RoW | Dapagliflozin, Empagliflozin, Canagliflozin, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin | Alexandria University | Type 2 Diabetes | 12/23 | 12/23 | | |
| Completed | N/A | 60 | RoW | Liraglutide / Semaglutide, GLP1RA alone, Dapagliflozin, SGLT2i alone, Liraglutide or Semaglutide / Dapagliflozin, Combination of GLP1RA and SGLT2i, Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition, Combination of GLP1RA, SGLT2i and intensive weight loss nutrition, Usual care | Dasman Diabetes Institute | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT06147518: To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis |
|
|
| Not yet recruiting | N/A | 240 | RoW | Metformin, Sitagliptin, Dapagliflozin | Institute of Liver and Biliary Sciences, India | Compensated Cirrhosis, Decompensated Cirrhosis | 12/24 | 12/24 | | |
OPTIMISE-CKD, NCT06203704: Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients |
|
|
| Recruiting | N/A | 1090 | Europe, RoW | | AstraZeneca | Chronic Kidney Disease (CKD) | 09/25 | 09/25 | | |
NCT06201000: Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients |
|
|
| Recruiting | N/A | 282 | US | SGLT2 inhibitors (Dapagliflozin and Empagliflozin), Forxiga, Jardiance | October 6 University, University of Florida, National Heart Institute, Egypt, Beni-Suef University | Genetic Polymorphisms, Heart Failure | 07/24 | 09/24 | | |
| Active, not recruiting | N/A | 287 | Europe | | AstraZeneca | Heart Failure | 12/23 | 12/23 | | |
NCT06187493: Treatment of Patients With Diabetic Kidney Disease |
|
|
| Not yet recruiting | N/A | 70 | NA | lisinopril, enalapril, dapagliflozin, empagliflozin | Assiut University | Diabetic Kidney Disease | 01/25 | 12/25 | | |
| Recruiting | N/A | 70 | Europe | Follow-up at D14, Follow-up at M1 | University Hospital, Montpellier | Chronic Kidney Diseases | 07/24 | 01/25 | | |
| Completed | N/A | 239 | Europe | | AstraZeneca | Heart Failure | 03/24 | 03/24 | | |
NCT06398977: Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients |
|
|
| Recruiting | N/A | 70 | RoW | Dapagliflozin, dagliflozin | Sichuan Academy of Medical Sciences | Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors | 06/26 | 12/26 | | |
NCT06297681: Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease |
|
|
| Not yet recruiting | N/A | 40 | NA | Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin | Beijing Chao Yang Hospital, Beijing Chuiyangliu Hospital, Beijing Boren Hospital | M-protein Related Cardiac Disease | 01/25 | 12/25 | | |
NCT05849220: Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease. |
|
|
| Not yet recruiting | N/A | 144 | RoW | Dapagliflozin, Standard of Care | Institute of Liver and Biliary Sciences, India | NAFLD Cirrhosis | 03/24 | 03/24 | | |
| Active, not recruiting | N/A | 1221 | Japan | | AstraZeneca | Heart Failure | 12/24 | 12/24 | | |
ChiCTR2200061227: Evidence-based capacity building project for the prevention and treatment of type 2 diabetes with traditional Chinese medicine—a multi-center randomized controlled clinical study on the treatment of newly diagnosed type 2 diabetes with damp-heat syndrome by Huashi Jiangzhuo prescription |
|
|
| Not yet recruiting | N/A | 108 | | Huashi Jiangzhuo prescription + dapagliflozin ;placebo + dapagliflozin | Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Evidence-based Capacity Building Project of Chinese Medicine in Chinese Academy of Traditional Chinese Medicine | type 2 diabetes mellitus | | | | |
NCT06090487: Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance |
|
|
| Recruiting | N/A | 30 | RoW | myocardial function after surgery | Ain Shams University | Heart Failure | 04/24 | 04/24 | | |
| Recruiting | N/A | 72 | RoW | Dapagliflozin Propanediol Hydrate 12.3 mg, Forxiga Tablet 10mg | Samsung Medical Center | Tricuspid Regurgitation | 04/24 | 03/25 | | |
EVOLUTION-HF, NCT05250011: Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice |
|
|
| Completed | N/A | 252 | Europe | Dapagliflozin, Forxiga | AstraZeneca, Fullcro s.r.l. | Heart Failure, Reduced Ejection Fraction | 04/24 | 04/24 | | |
| Recruiting | N/A | 1000 | Europe | | AstraZeneca | Heart Diseases, Cardiovascular Diseases, Heart Failure | 09/26 | 09/26 | | |
ChiCTR2200058761: Clinical assessment of dapagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus: study protocol for a single-center, randomized, double-blind control trial |
|
|
| Not yet recruiting | N/A | 120 | | dapagliflozin ;conventional therapy | Taizhou First People's Hospital; Level of the institution：, Basic Public Welfare Research Project of Zhejiang Province | diabetes | | | | |
| Not yet recruiting | N/A | 100 | NA | SGLT2 inhibitor, Dapagliflozin and Empagliflozin | Assiut University | Perioperative Complication | 04/25 | 10/25 | | |
NCT05134701: Dapagliflozin Post Marketing Surveillance in HF and CKD |
|
|
| Active, not recruiting | N/A | 815 | RoW | | AstraZeneca | Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease | 10/24 | 10/24 | | |
DARE-AF, NCT06433479: Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation |
|
|
| Not yet recruiting | N/A | 200 | RoW | Dapagliflozin 10 mg per day for 3 months after initial catheter ablation | Beijing Anzhen Hospital | Atrial Fibrillation | 08/25 | 04/26 | | |
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
|
|
| Active, not recruiting | N/A | 781430 | US | SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University | Cardiovascular Events, Type2 Diabetes, Renal Disease | 07/24 | 07/24 | | |
Dapa-LiT, NCT05042505: Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation |
|
|
| Recruiting | N/A | 100 | RoW | Dapagliflozin 10Mg Tab, Sitagliptin 100mg | Medanta, The Medicity, India | Diabetes Mellitus, Liver Transplant; Complications | 08/24 | 08/24 | | |
ChiCTR2200063310: Incidence of diabetes remission after a short-term intensive intervention with insulin, dapagliflozin, and metformin in patients with type 2 diabetes mellitus |
|
|
| Not yet recruiting | N/A | 148 | | Short-term intensive insulin therapy ;Short-term intensive intervention with insulin, metformin, and dapagliflozin | The first People's Hospital of Xuzhou; The first People's Hospital of Xuzhou, Project funding | Type 2 diabetes mellitus | | | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 12/24 | 07/25 | | |
NCT05033054: Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4 |
|
|
| Recruiting | N/A | 28 | US | SGLT2 inhibitor | University of Texas Southwestern Medical Center | Kidney Disease, Chronic, Diabetes | 12/24 | 12/24 | | |
NCT05970237: A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension |
|
|
| Recruiting | N/A | 9000 | RoW | | Boryung Pharmaceutical Co., Ltd | Diabetes Mellitus, Hypertension | 12/24 | 12/24 | | |
DAPA-GUT, NCT05965440: Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients |
|
|
| Recruiting | N/A | 50 | Europe | impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients | Hospices Civils de Lyon | Chronic Kidney Diseases | 12/24 | 12/24 | | |
NCT02695121: Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment |
|
|
| Recruiting | N/A | 1125000 | Europe, US | | AstraZeneca | Breast Cancer, Bladder Cancer | 12/24 | 12/24 | | |
NCT05795400: Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy |
|
|
| Recruiting | N/A | 40 | RoW | Dapagliflozin 10mg Tab, Placebo | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy | 01/25 | 06/25 | | |
| Active, not recruiting | N/A | 257 | Europe | | AstraZeneca | Heart Failure | 03/25 | 03/25 | | |
NCT05770167: Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure |
|
|
| Recruiting | N/A | 70 | Europe | | Centro Cardiologico Monzino | Heart Failure, Heart Failure With Reduced Ejection Fraction, Left Ventricle Remodeling, Sleep Apnea, Cardiopulmonary Exercise Test | 04/25 | 04/25 | | |
NCT05306210: Forxiga CKD Japan Post-Marketing Surveillance (PMS) |
|
|
| Active, not recruiting | N/A | 1029 | Japan | | AstraZeneca | Chronic Kidney Disease | 04/25 | 04/25 | | |
| Recruiting | N/A | 100 | RoW | Dapagliflozin | Chinese University of Hong Kong | Heart Failure | 09/25 | 12/25 | | |
ChiCTR2200064578: Dapagliflozin added as replenishment of elaborated stardard therapy for sepsis admitied to ICU |
|
|
| Not yet recruiting | N/A | 200 | | 10 mg Dapagliflozin each day and regular therapy ;Regular therapy | Strategic Support Force Medical Center; Strategic Support Force Medical Center, Research Project of the Strategic Support Force Characteristic Medical Center: 21ZX09 | Sepsis | | | | |
RECORD-AMI, NCT05770687: SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study |
|
|
| Recruiting | N/A | 1000 | RoW | SGLT2 inhibitor, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin | Kiyuk Chang, Seoul St. Mary's Hospital, Uijeongbu St. Mary Hospital, Incheon St.Mary's Hospital, Daejeon St. Mary's hospital, Bucheon St. Mary's Hospital, St Vincent's Hospital, Yeouido St. Mary's Hospital, Sejong General Hospital, Pusan National University Hospital, Andong Hospital, Chungnam National University Hospital, St. Carollo General Hospital, Pusan National University Yangsan Hospital, Kyungpook National University Hospital, Jeju National University Hospital, Korea University Anam Hospital, Inje University | Myocardial Infarction, Diabetes Mellitus, Type 2 | 12/25 | 12/26 | | |
ChiCTR2300074487: A multicenter prospective randomized controlled trial of dapagliflozin combined with angiotensin receptor inhibitors for the prevention and treatment of heart failure in peritoneal dialysis patients |
|
|
| Not yet recruiting | N/A | 100 | | Dapagliflozin in combination with RASi; RASi only | Shanghai East Hospital (East Hospital Affiliated to Tongji University）; Shanghai East Hospital (East Hospital Affiliated to Tongji University）, Research funding | end stage renal disease | | | | |
NCT06009874: Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI |
|
|
| Recruiting | N/A | 80 | RoW | Dapagliflozin 10mg Tab, DAPA, Placebo | Mohammad Hussien Tantawy Soliman | Myocardial Infarction | 08/26 | 08/26 | | |
| Not yet recruiting | N/A | 50 | NA | Other, Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin | Imperial College London, Royal Brompton & Harefield NHS Foundation Trust | Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies, Heart Diseases | 08/26 | 09/26 | | |
ChiCTR2100042502: A study of Dapagliflozin to improve left ventricular stress in heart failure patients with preserved ejection fraction |
|
|
| Recruiting | N/A | 100 | | Daglidine + conventional treatment ;Conventional treatment | Jinan Central Hospital; Jinan Central Hospital, Project funding | Heart failure with preserved ejection fraction | | | | |
